Immuneering Granted U.S. Composition Patent for Highly Differentiated Cancer Drug Candidate

Immuneering (Nasdaq: IMRX) has secured a crucial U.S. composition of matter patent for atebimetinib, its innovative cancer drug candidate. The patent, expected to provide exclusivity until August 2042, covers this first-in-class deep cyclic MEK inhibitor designed as a once-daily pill to combat cancer drug resistance.

Clinical data has shown remarkable results, with 94% probability of 6-month survival in first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, compared to 67% with standard care. The drug has received FDA Fast Track designations for first- and second-line pancreatic cancer treatment and NRAS-mutant melanoma, along with orphan drug designation for pancreatic cancer.

https://www.stocktitan.net/news/IMRX/immuneering-granted-u-s-composition-of-matter-patent-for-highly-6hp1kavekgie.html